Alcyomics

Alcyomics  is a service provider,  specialising  but not limited to predicting adverse immune reactions to  novel compounds and drugs including, monoclonal antibodies  and  cellular therapies and  has 3 EU and US patents with one further patent filed. Alcyomics Skimune® platform uses human skin biopsies and  blood samples , with local research ethics committee approval,  to  assess  novel drugs and compounds for adverse immune reactions  with readouts including T cell proliferation, cytokine release and  histopathological damage, a unique, accurate  and sensitive readout. The assay, unlike others on the market covers all aspects of the Adverse Outcome Pathway. 

About us

Our mission at Alcyomics is to provide novel solutions for pre-clinical drug safety and efficacy testing of therapeutics including cellular therapies which is also extended to the chemical and cosmetic industries. As a Service provider Alcyomics  aspires to take the lead in providing unique screening services using human in vitro skin explant assays enabling more cost effective commercialisation of products and or drugs. Alcyomics development pipeline includes drug discovery disease modelling for  the identification of novel drug targets.

Alcyomics has clients in the USA, Europe and Japan and includes  some of the top ten pharma and cosmetics companies. We have also worked with companies in the medical device industry and have assessed complex formulations. We currently carry out assays  to IS9001 standard, where  the results go towards the  investigative medical product dossier  for regulatory approval in both the UK and Japan. In addition Alcyomics also specialises in  disease models ( osteoarthritis and skin disease- atopic dermatitis) using human derived cell lines  and or human skin tissue for drug screening, efficacy and drug discovery.

Highlights

• Alcyomics can also offer a range of  OECD approved assays covering skin corrosion, sensitisation, irritation, wound healing (scratch assays) and senescence  assays for assessment of compounds targeted at  the aging process. Benefits to users of Alcyomics assays enable cost saving in reducing the need for extensive animal experimentation, accurate prediction of  systemic and skin adverse immune  events, sensitive drug efficacy testing  and novel platforms for drug discovery.
• Alcyomics technology is also a reliable alternative to animal testing for safety and potency assessment of novel compounds. 
  Pre-clinical service provider using Skimune^®, non-artificial human skin explants for predicting adverse immune reactions  as well as determining efficacy  of novel compounds including pharmaceuticals, chemicals and cosmetics.
  
• We also offer a consultancy service of how the pre-clinical data can be used to assist clinical trial development such as dose response and assist in developing stratified medicine/ precision medicine  approaches to patient selection.

Website | https://www.alcyomics.com

Schedule a 1:1 business networking meeting with Alcyomics